Exclusive distribution partnership with TPVN Pharmaceutical brings Finnish dual-light antibacterial home-care technology to one of Asia’s fastest-growing dental markets, a market of 119 million people and more than 100,000 dental implants placed each year.
HELSINKI, FINLAND, April 13, 2026. Koite Health Oy, the Finnish health technology company behind Lumoral, a clinically validated at-home antibacterial light treatment for oral and periodontal care, today announced the commercial launch of Lumoral in Vietnam through an exclusive distribution partnership with TPVN Pharmaceutical Limited Company. The launch marks Koite Health’s first entry into Southeast Asia and establishes Vietnam as a reference market for the company’s broader Asia strategy.
The Vietnam launch follows the granting of local sales authorization and builds on a partnership first initiated at the 2025 International Dental Show (IDS) in Cologne. Vietnam is one of Asia’s most dynamic dental markets, with 119 million people served by tens of thousands of dentists and thousands of private clinics. Over 100,000 dental implants are placed in the country every year, giving Lumoral a clearly defined target segment alongside orthodontic and periodontitis patients. Vietnam has also emerged as an early adopter of new dental technology in Asia, with clinics quick to integrate the latest innovations.
TPVN Pharmaceutical, an established distributor of dental products in Vietnam, will lead professional sales into the country’s clinic network. The launch is supported by early engagement with leading key opinion leaders, including Associate Professor Nguyễn Thu Thủy, Vice Head of the Faculty of Odonto-Stomatology and Head of the Department of Periodontology at the University of Medicine and Pharmacy. At a recent national dental congress, Prof. Dr. Werner Birglechner, a leading European dental specialist, delivered two lectures on personalised periodontal care and the patented technology behind Lumoral, generating strong professional interest. The newly published HOPE-CP clinical study provides the scientific foundation for TPVN’s clinic rollout. 
Lumoral’s professional launch has been accompanied by broad national media coverage in Vietnam, including features in Tuổi Trẻ, Nhân Dân, VnExpress, Tiền Phong, and Người Lao Động, creating immediate awareness for the brand and supporting professional adoption. 
“Lumoral as a new technology, meets Vietnam’s growing need for an effective treatment method within a fast-growing population,” said Tero Pasanen, Chief Commercial Officer at Koite Health. “Our partner TPVN has a ready channel into thousands of clinics, the HOPE-CP clinical evidence has arrived at the right time, and Prof. Birglechner’s lectures created professional demand before the first unit shipped. That combination is rare in a new market and gives Lumoral a strong starting position.”
“Our core growth engine remains the European Union, but new EU trade agreements with Australia and India, together with the Mercosur agreement in South America, are opening clear global pathways,” Pasanen added. “Vietnam is both a commercial market in its own right and a reference point for the rest of Southeast Asia.”
About Lumoral
Lumoral is a clinically validated, at-home dual-light antibacterial treatment developed to manage oral biofilm. It is used in the care of periodontitis, peri-implantitis, and orthodontic patients, alongside Lumorinse mouth rinse tablets. Lumoral is CE-marked and distributed through dental professionals across Europe, selected countries outside of EU and, now, Vietnam.
About Koite Health
Koite Health Oy is a Finnish health technology company commercializing dual-light activated antibacterial therapy for oral health. The company holds multiple patents on its core technology and works with dental professionals and research institutions internationally. Its primary growth market is the European Union, with selective expansion into global markets.
Leave a comment
This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.